siRNA targeting the Leader sequence of SARS-CoV inhibits virus replication

Abstract

SARS-CoV (the SARS-Associated Coronavirus) was reported as a novel virus member in the coronavirus family, which was the cause of severe acute respiratory syndrome. Coronavirus replication occurs through a unique mechanism employing Leader sequence in the transcripts when initiating transcription from the genome. Therefore, we cloned the Leader sequence from SARS-CoV(BJ01), which is identical to that identified from SARS-CoV(HKU-39849), and constructed specific siRNA targeting the Leader sequence. Using EGFP and RFP reporter genes fused with the cloned SARS-CoV Leader sequence, we demonstrated that the siRNA targeting the Leader sequence decreased the mRNA abundance and protein expression levels of the reporter genes in 293T cells. By stably expressing the siRNA in Vero E6 cells, we provided data that the siRNA could effectively and specifically decrease the mRNA abundance of SARSCoV genes as analyzed by RT-PCR and Northern blot. Our data indicated that the siRNA targeting the Leader sequence inhibited the replication of SARS-CoV in Vero E6 cells by silencing gene expression. We further demonstrated, via transient transfection experiments, that the siRNA targeting the Leader sequence had a much stronger inhibitory effect on SARS-CoV replication than the siRNAs targeting the Spike gene or the antisense oligodeoxynucleotides did. This report provides evidence that targeting Leader sequence using siRNA could be a powerful tool in inhibiting SARS-CoV replication. Gene Therapy (2005) 12, 751-761.

A Novel Function of dcf1 During the Differentiation of Neural Stem Cells In vitro

“…Those sequences start with an A, which corresponds to the transcription initiation point of the H1 promoter. As an empirical design, we preferably chose the sites with Cell Mol Neurobiol (2008) 28:887-894 889 GC/AT ratios between 30 and 60% (Li et al 2005). Also we used the selected sequences to search GenBank to confirm their specificity.…”

How Prepared Are We to Control Severe Acute Respiratory Syndrome in Future

“…It was reported to be 10 or 100 times more potent inhibitor of SARS-CoV than IFN-∝ and IFN-β, respectively (He et al, 2004) Chloroquine A clinically approved drug for malaria was effective with an IC50 in lower µM range (Keyaerts et al, 2004). In addition to its effect through elevation of endosomal pH, chloroquine seems to interfere with terminal glycosylation of ACE2, the the receptor for SARS-CoV (Vincent et al, 2005 (Li et al, 2005a;Wu and Huang, 2005;Zhao and Qin, 2005;Tang and Li, 2008) Homology modeling also formed a basis for designing mechanism-based irreversible inhibitors of 3CLpro with an activity of wide spectrum across coronaviruses (Yang et al, 2005a). Besides, several groups have identified a number of inhibitors of 3CLpro using a variety of approaches.…”

“…Sequence analysis showed that there was a significant homology between bat and human viruses. Interestingly, the 29-nucleotides in the ORF-8 was present in the virus of bat origin and the most variability between the two was found to be in the S1 region of spike protein, which is responsible for receptor binding (Li et al, 2005a). Findings from all such studies were put together to establish origin of SARS-CoV.…”

RNA Interference-Based Therapeutics: Harnessing the Powers of Nature

“…In order to obtain durable and effective antiviral therapies, viral proteins that can be disabled need to be identified. Ideally, these targets should be essential factors that share conserved sequences across many www.intechopen.com different strains or even among different species of virus of the same family, so that a single target will have broad effectiveness (Das et al, 2004;Wilson & Richardson, 2005 (Jung et al, 2010;Palanichamy et al, 2010), influenza viruses A (Seth et al, 2010;Zhiqiang et al, 2010), respiratory syncytial virus (RSV) (Bitko & Barik, 2001;Bitko, et al, 2005;DeVincenzo, J.P. et al, 2010;Zamora et al, 2010), herpes simplex virus 2 (Palliser et al, 2006), West Nile virus (WNV) (Anthony et al, 2009;Ye et al, 2011), severe acute respiratory syndrome (SARS) virus (Li et al, 2005;Wu & Chan, 2006) and cytomegalovirus (CMV) (Wiebusch et al, 2004). Sereval R&D programs are currently focusing their efforts on infection diseases, HIV is one of these examples.…”